1.A Multimodal Ensemble Deep Learning Model for Functional Outcome Prognosis of Stroke Patients
Hye-Soo JUNG ; Eun-Jae LEE ; Dae-Il CHANG ; Han Jin CHO ; Jun LEE ; Jae-Kwan CHA ; Man-Seok PARK ; Kyung Ho YU ; Jin-Man JUNG ; Seong Hwan AHN ; Dong-Eog KIM ; Ju Hun LEE ; Keun-Sik HONG ; Sung-Il SOHN ; Kyung-Pil PARK ; Sun U. KWON ; Jong S. KIM ; Jun Young CHANG ; Bum Joon KIM ; Dong-Wha KANG ;
Journal of Stroke 2024;26(2):312-320
Background:
and Purpose The accurate prediction of functional outcomes in patients with acute ischemic stroke (AIS) is crucial for informed clinical decision-making and optimal resource utilization. As such, this study aimed to construct an ensemble deep learning model that integrates multimodal imaging and clinical data to predict the 90-day functional outcomes after AIS.
Methods:
We used data from the Korean Stroke Neuroimaging Initiative database, a prospective multicenter stroke registry to construct an ensemble model integrated individual 3D convolutional neural networks for diffusion-weighted imaging and fluid-attenuated inversion recovery (FLAIR), along with a deep neural network for clinical data, to predict 90-day functional independence after AIS using a modified Rankin Scale (mRS) of 3–6. To evaluate the performance of the ensemble model, we compared the area under the curve (AUC) of the proposed method with that of individual models trained on each modality to identify patients with AIS with an mRS score of 3–6.
Results:
Of the 2,606 patients with AIS, 993 (38.1%) achieved an mRS score of 3–6 at 90 days post-stroke. Our model achieved AUC values of 0.830 (standard cross-validation [CV]) and 0.779 (time-based CV), which significantly outperformed the other models relying on single modalities: b-value of 1,000 s/mm2 (P<0.001), apparent diffusion coefficient map (P<0.001), FLAIR (P<0.001), and clinical data (P=0.004).
Conclusion
The integration of multimodal imaging and clinical data resulted in superior prediction of the 90-day functional outcomes in AIS patients compared to the use of a single data modality.
2.Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines
Hyun-Woong CHO ; Kyung-Jin MIN ; Sang-Hoon KWON ; Kidong KIM ; Sunghoon KIM ; Seok Ju SEONG ; Yong Jung SONG ; Keun Ho LEE ; Shin-Wha LEE ; Jeong-Won LEE ; Woong JU ; Young Tae KIM ; Jae Kwan LEE
Journal of Gynecologic Oncology 2021;32(6):e94-
Since the human papillomavirus (HPV) vaccine guidelines were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2011, 2016, and 2019, several recent studies on the efficacy and safety of HPV vaccines in middle-aged women and men have been reported. Furthermore, there has been an ongoing debate regarding the efficacy of the HPV vaccine in women with prior HPV infection or who have undergone conization for cervical intraepithelial neoplasia (CIN). We searched and reviewed studies on the efficacy and safety of the HPV vaccine in middle-aged women and men and the efficacy of the HPV vaccine in patients infected with HPV and those who underwent conization for CIN. The KSGO updated their guidelines based on the results of the studies included in this review.
3.Changes in High-Density Lipoprotein Cholesterol and Risks of Cardiovascular Events: A Post Hoc Analysis from the PICASSO Trial
Eun-Jae LEE ; Sun U. KWON ; Jong-Ho PARK ; Yong-Jae KIM ; Keun-Sik HONG ; Sungwook YU ; Yang-Ha HWANG ; Ji Sung LEE ; Juneyoung LEE ; Joung-Ho RHA ; Sung Hyuk HEO ; Sung Hwan AHN ; Woo-Keun SEO ; Jong-Moo PARK ; Ju-Hun LEE ; Jee-Hyun KWON ; Sung-Il SOHN ; Jin-Man JUNG ; Hahn Young KIM ; Eung-Gyu KIM ; Sung Hun KIM ; Jae-Kwan CHA ; Man-Seok PARK ; Hyo Suk NAM ; Dong-Wha KANG ;
Journal of Stroke 2020;22(1):108-118
Background:
and purpose Whether pharmacologically altered high-density lipoprotein cholesterol (HDL-C) affects the risk of cardiovascular events is unknown. Recently, we have reported the Prevention of Cardiovascular Events in Asian Patients with Ischaemic Stroke at High Risk of Cerebral Haemorrhage (PICASSO) trial that demonstrated the non-inferiority of cilostazol to aspirin and superiority of probucol to non-probucol for cardiovascular prevention in ischemic stroke patients (clinicaltrials.gov: NCT01013532). We aimed to determine whether on-treatment HDL-C changes by cilostazol and probucol influence the treatment effect of each study medication during the PICASSO study.
Methods:
Of the 1,534 randomized patients, 1,373 (89.5%) with baseline cholesterol parameters were analyzed. Efficacy endpoint was the composite of stroke, myocardial infarction, and cardiovascular death. Cox proportional hazards regression analysis examined an interaction between the treatment effect and changes in HDL-C levels from randomization to 1 month for each study arm.
Results:
One-month post-randomization mean HDL-C level was significantly higher in the cilostazol group than in the aspirin group (1.08 mmol/L vs. 1.00 mmol/L, P<0.001). The mean HDL-C level was significantly lower in the probucol group than in the non-probucol group (0.86 mmol/L vs. 1.22 mmol/L, P<0.001). These trends persisted throughout the study. In both study arms, no significant interaction was observed between HDL-C changes and the assigned treatment regarding the risk of the efficacy endpoint.
Conclusions
Despite significant HDL-C changes, the effects of cilostazol and probucol treatment on the risk of cardiovascular events were insignificant. Pharmacologically altered HDL-C levels may not be reliable prognostic markers for cardiovascular risk.
4.Reliability and Clinical Utility of Machine Learning to Predict Stroke Prognosis: Comparison with Logistic Regression
Su-Kyeong JANG ; Jun Young CHANG ; Ji Sung LEE ; Eun-Jae LEE ; Yong-Hwan KIM ; Jung Hoon HAN ; Dae-Il CHANG ; Han Jin CHO ; Jae-Kwan CHA ; Kyung Ho YU ; Jin-Man JUNG ; Seong Hwan AHN ; Dong-Eog KIM ; Sung-Il SOHN ; Ju Hun LEE ; Kyung-Pil PARK ; Sun U. KWON ; Jong S. KIM ; Dong-Wha KANG ;
Journal of Stroke 2020;22(3):403-406
5.The Management of Retained Rectal Foreign Body
Ju Hun KIM ; Eunhae UM ; Sung Min JUNG ; Yong Chan SHIN ; Sung-Won JUNG ; Jae Il KIM ; Tae Gil HEO ; Myung Soo LEE ; Heungman JUN ; Pyong Wha CHOI
Annals of Coloproctology 2020;36(5):335-343
Purpose:
Because insertion of a foreign body (FB) into the anus is considered a taboo practice, patients with a retained rectal FB may hesitate to obtain medical care, and attending surgeons may lack experience with removing these FBs. We performed this study to evaluate the clinical characteristics of Korean patients with a retained rectal FB and propose management guideline for such cases based on our experience.
Methods:
We retrospectively investigated 14 patients between January 2006 and December 2018. We assessed demographic features, mechanism of FB insertion, clinical course between diagnosis and management, and outcomes.
Results:
All patients were male (mean age, 43 years) and presented with low abdominal pain (n = 2), anal bleeding (n = 2), or concern about a retained rectal FB without symptoms (n = 10). FB insertion was most commonly associated with sexual gratification or anal eroticism (n = 11, 78.6%). All patients underwent general anesthesia for anal sphincter relaxation with the exception of 2 who underwent FB removal in the emergency department. FBs were retrieved transanally using a clamp (n = 2), myoma screw (n = 1), clamp application following abdominal wall compression (n = 2), or laparotomy followed by rectosigmoid colon milking (n = 2). Colotomy and primary repair were performed in four patients, and Hartmann operation was performed in one patient with fecal peritonitis. No morbidity or mortality was reported. All patients refused postextraction anorectal functional and anatomical evaluation and psychological counseling.
Conclusion
Retained rectal FB is rare; however, colorectal surgeons should be aware of the various methods that can be used for FB retrieval and the therapeutic algorithm applicable in such cases.
6.Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study
Haeryoung KIM ; Soyeon AN ; Kyoungbun LEE ; Sangjeong AHN ; Do Youn PARK ; Jo-Heon KIM ; Dong-Wook KANG ; Min-Ju KIM ; Mee Soo CHANG ; Eun Sun JUNG ; Joon Mee KIM ; Yoon Jung CHOI ; So-Young JIN ; Hee Kyung CHANG ; Mee-Yon CHO ; Yun Kyung KANG ; Myunghee KANG ; Soomin AHN ; Youn Wha KIM ; Seung-Mo HONG ;
Cancer Research and Treatment 2020;52(1):263-276
Purpose:
The most recent 2017 World Health Organization (WHO) classification of pancreatic neuroendocrine neoplasms (PanNENs) has refined the three-tiered 2010 scheme by separating grade 3 pancreatic neuroendocrine tumors (G3 PanNETs) from poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs). However, differentiating between G3 Pan- NETs and PanNECs is difficult in clinical practice.
Materials and Methods:
Eighty-two surgically resected PanNENs were collected from 16 institutions and reclassified according to the 2017 WHO classification based on the histological features and proliferation index (mitosis and Ki-67). Immunohistochemical stains for ATRX, DAXX, retinoblastoma, p53, Smad4, p16, and MUC1 were performed for 15 high-grade PanNENs.
Results:
Re-classification resulted in 20 G1 PanNETs (24%), 47 G2 PanNETs (57%), eight G3 well-differentiated PanNETs (10%), and seven poorly differentiated PanNECs (9%). PanNECs showed more frequent diffuse nuclear atypia, solid growth patterns and apoptosis, less frequent organoid growth and regular vascular patterns, and absence of low-grade PanNET components than PanNETs. The Ki-67 index was significantly higher in PanNEC (58.2%± 15.1%) compared to G3 PanNET (22.6%±6.1%, p < 0.001). Abnormal expression of any two of p53, p16, MUC1, and Smad4 could discriminate PanNECs from G3 PanNETs with 100% specificity and 87.5% sensitivity.
Conclusion
Histological features supporting the diagnosis of PanNECs over G3 PanNETs were the absence of a low-grade PanNET component in the tumor, the presence of diffuse marked nuclear atypia, solid growth pattern, frequent apoptosis and markedly increased proliferative activity with homogeneous Ki-67 labeling. Immunohistochemical stains for p53, p16, MUC1, and Smad4 may be helpful in distinguishing PanNECs from G3 PanNETs in histologically ambiguous cases, especially in diagnostic practice when only small biopsied tissues are available.
7.Asian Society of Gynecologic Oncology International Workshop 2018
Tae Wook KONG ; Hee Sug RYU ; Seung Cheol KIM ; Takayuki ENOMOTO ; Jin LI ; Kenneth H KIM ; Seung Hyuk SHIM ; Peng Hui WANG ; Suwanit THERASAKVICHYA ; Yusuke KOBAYASHI ; Maria LEE ; Tingyan SHI ; Shin Wha LEE ; Mikio MIKAMI ; Satoru NAGASE ; Myong Cheol LIM ; Jianliu WANG ; Sarikapan WILAILAK ; Sang Wun KIM ; Sook Hee HONG ; David SP TAN ; Masaki MANDAI ; Suk Joon CHANG ; Ruby Yun Ju HUANG ; Kimio USHIJIMA ; Jung Yun LEE ; Xiaojun CHEN ; Kazunori OCHIAI ; Taek Sang LEE ; Bingyi YANG ; Farhana KALAM ; Qiaoying LV ; Mohd Faizal AHMAD ; Muhammad Rizki YAZNIL ; Kanika Batra MODI ; Manatsawee MANOPUNYA ; Dae Hoon JEONG ; Arb aroon LERTKHACHONSUK ; Hyun Hoon CHUNG ; Hidemichi WATARI ; Seob JEON
Journal of Gynecologic Oncology 2019;30(2):e39-
The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discuss the latest findings of gynecologic cancer, including cervical, ovarian, and endometrial cancers, as well as the future of fertility-sparing treatments, minimally invasive/radical/debulking surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Clinical guidelines and position statement of Asian countries were presented by experts. Asian clinical trials for gynecologic cancers were reviewed and experts emphasized the point that original Asian study is beneficial for Asian patients. In Junior session, young gynecologic oncologists presented their latest research on gynecologic cancers.
Antineoplastic Agents
;
Asian Continental Ancestry Group
;
Drug Therapy
;
Education
;
Endometrial Neoplasms
;
Female
;
Gyeonggi-do
;
Humans
;
Immunotherapy
;
Korea
;
Ovarian Neoplasms
;
Radiotherapy
;
Uterine Cervical Neoplasms
8.Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline
Kyung Jin MIN ; Sang Hoon KWON ; Kidong KIM ; Sunghoon KIM ; Hyun Jung KIM ; Seok Ju SEONG ; Yong Jung SONG ; Keun Ho LEE ; Shin Wha LEE ; Jeong Won LEE ; Suk Joon CHANG ; Woong JU ; Young Tak KIM ; Jae Kwan LEE
Journal of Gynecologic Oncology 2019;30(2):e31-
In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.
Appointments and Schedules
;
Female
;
Humans
;
Korea
;
Male
;
Papillomavirus Vaccines
;
Vaccination
9.Surveillance Rate and its Impact on Survival of Hepatocellular Carcinoma Patients in South Korea: A Cohort Study
Sanghyuk IM ; Eun Sun JANG ; Ju Hyun LEE ; Chung Seop LEE ; Beom Hee KIM ; Jung Wha CHUNG ; Jin Wook KIM ; Sook Hyang JEONG
Cancer Research and Treatment 2019;51(4):1357-1369
PURPOSE: Though regular surveillance of hepatocellular carcinoma (HCC) for high-risk patients is widely recommended, its rate and effectiveness are not clear. The aim of this study is to investigate the actual rate of HCC surveillance and its related factors and to clarify its impact on survival in a Korean HCC cohort. MATERIALS AND METHODS: From 2012 to 2015, 319 newly diagnosed HCC patients were prospectively enrolled at a tertiary hospital. Patient interviews based on a structured questionnaire survey were conducted. Surveillance was defined as liver imaging test ≥ 2 times with at least 3-month interval within 2 years prior to HCC diagnosis. RESULTS: Surveillance rate was 39.8%. Of the HCC patients with high-risk factors, only 182 (57.1%) had knowledge for the need for regular surveillance, and 141 (44.2%) had the accurate information about the method (ultrasound-based study). Surveillance group showed a higher proportion of early HCC (p < 0.001) and a longer overall survival (p < 0.001) compared to non-surveillance group. The multivariable Cox regression analysis indicated Child-Pugh class A, history of anti-viral therapy, low serum α-fetoprotein level, non-advanced Barcelona Clinic Liver Cancer stage as independent predictors of overall survival, while regular surveillance was not (p=0.436). CONCLUSION: Less than half of the newly diagnosed Korean HCC patients were under surveillance and the accurate perception for the need of HCC surveillance was insufficient. Of those under surveillance, most patients were diagnosed with early stage HCC, which led to the improved survival. Comprehensive efforts to optimize the surveillance program for the target population are warranted.
Carcinoma, Hepatocellular
;
Cohort Studies
;
Diagnosis
;
Health Services Needs and Demand
;
Humans
;
Korea
;
Liver
;
Liver Cirrhosis
;
Liver Neoplasms
;
Mass Screening
;
Methods
;
Prospective Studies
;
Tertiary Care Centers
10.Comparative in vivo biodistributions of nanoparticles and polymers of ¹⁷⁷lutetium-labeled hyaluronic acids in mice during 28 days.
Chunmei LIN ; Ju Yeon JEONG ; Jung Min YON ; Seul Gi PARK ; Lee Wha GWON ; Jong Geol LEE ; In Jeoung BAEK ; Sang Soep NAHM ; Beom Jun LEE ; Young Won YUN ; Sang Yoon NAM
Korean Journal of Veterinary Research 2017;57(2):105-111
Hyaluronic acid (HA) has been investigated for biomedical and pharmaceutical applications. This study was conducted to determine the distributions of HA nanoparticles (NPs; size 350–400 nm) and larger HA polymers in mice at intervals after application. ¹⁷⁷Lutetium (Lu)-labeled HA-NPs or HA polymers were intravenously injected (5 mg/kg) into male ICR mice, and radioactivity levels in blood and target organs were measured from 0.25 h to 28 days post-injection. In blood, the radioactivities of HA-NPs and HA polymer peaked at 0.5 h after injection but were remarkably decreased at 2 h; subsequently, they maintained a constant level until 6 days post-injection. HA-NPs and HA polymers were observed in the liver, spleen, lung, kidney, and heart (in ascending order) but were seldom observed in other organs. After 3 days, both the HA-NP and HA polymer levels showed similar steady decreases in lung, kidney, and heart. However, in liver and spleen, the HA-NP levels tended to decrease gradually after 1 day and both were very low after 14 days, whereas the HA polymer level accumulated for 28 days. The results indicate that HA-NPs, with their faster clearance pattern, may act as a better drug delivery system than HA polymers, especially in the liver and spleen.
Animals
;
Drug Delivery Systems
;
Heart
;
Humans
;
Hyaluronic Acid*
;
Kidney
;
Liver
;
Lung
;
Male
;
Mice*
;
Mice, Inbred ICR
;
Nanoparticles*
;
Polymers*
;
Radioactivity
;
Spleen

Result Analysis
Print
Save
E-mail